1. Introduction
===============

The first step in the metabolism of two classes of inflammatory phospholipid mediators, Platelet-Activating Factor (PAF) and oxidatively-fragmented phospholipids (OxPL), is catalyzed by enzymatic activities known as PAF acetylhydrolases (PAF-AHs). This family of phospholipases A~2~ includes intracellular and secreted activities. The secreted form of PAF-AH (also known as lipoprotein-associated phospholipase A~2~, LpPLA~2~, PLA~2~G7) circulates in plasma as a complex with high- and low-density lipoproteins (HDL and LDL, respectively). While the physiological consequences of dual lipoprotein association remain to be completely identified, it is apparent that the location of the enzyme impacts its function and that aberrant distribution is associated with a variety of syndromes. The role of PAF-AH in human biology continues to be the subject of intense research as increasing numbers of laboratories around the world are utilizing complementary approaches to examine the function of this enzyme *in vivo*. The well-recognized fact that altered expression of PAF-AH correlates with the incidence and severity of vascular and other inflammatory diseases has sparked the interest of a wide range of scientists and clinicians in both the public and private sectors. In addition, recent elegant work by Vadas and co-workers showed direct correlations between serum PAF levels and severity of anaphylaxis \[[@B1-pharmaceuticals-02-00094]\]. Importantly, PAF-AH activity was inversely correlated with disease severity and it was significantly lower in patients with fatal anaphylactic reactions than in patients in the control groups \[[@B1-pharmaceuticals-02-00094]\]. Considerable effort has been devoted to evaluating whether genetic variations in the PAF-AH gene are associated with the incidence and severity of human diseases, and whether these alterations affect the levels of protein expression and/or its function. A number of PAF-AH loss-of-function mutations and single nucleotide polymorphisms (SNPs) have been identified and studied to various extents with the objective of elucidating their impact in physiology and disease. These analyses have provided new mechanistic and clinical insights that may have important translational utility, including the potential for personalized diagnostic and therapeutic applications.

2. Naturally Occurring Genetic Alterations in the PAF-AH Gene
=============================================================

In humans, the PAF-AH gene harbors a number of mutations and polymorphisms within coding and non-coding regions ([Figure 1](#pharmaceuticals-02-00094-f001){ref-type="fig"}).

![Diagrammatic representation of mutations and polymorphisms in the PAF-AH gene.](pharmaceuticals-02-00094-g001){#pharmaceuticals-02-00094-f001}

The consequences of these genetic variations, particularly those that alter protein sequence, have been investigated in considerable detail in terms of the frequency with which they occur in both healthy and diseased subjects. One of the most thoroughly investigated variants is a loss-of-function mutation that occurs near the active site, and that has been observed mainly in Japanese \[[@B2-pharmaceuticals-02-00094]\], Taiwanese \[[@B3-pharmaceuticals-02-00094]\], Korean \[[@B4-pharmaceuticals-02-00094]\], and Chinese \[[@B5-pharmaceuticals-02-00094]\] populations. Three additional, but much less prevalent, loss-of-function mutations have been reported in Japanese subjects \[[@B6-pharmaceuticals-02-00094],[@B7-pharmaceuticals-02-00094]\]. In addition, the coding region of the PAF-AH gene harbors several SNPs that moderately impact enzymatic activity of the gene product; these will be discussed in subsequent sections. Genetic alterations have also been described in untranslated regions \[[@B8-pharmaceuticals-02-00094]\]. This article summarizes current information on the incidence and functional consequences of non-synonymous variants in the coding region of the gene. A discussion of SNPs located in promoter, intronic, and 3'-untranslated regions of PAF-AH is beyond the scope of this review.

3. Inactivating Mutations
=========================

PAF-AH deficiency was initially characterized by Miwa and co-workers using functional approaches \[[@B2-pharmaceuticals-02-00094]\]. This trait is quite prevalent in Japan, as approximately 4% of the population lacks expression of the activity in plasma \[[@B2-pharmaceuticals-02-00094]\]. In most cases, PAF-AH deficiency occurs as a consequence of a missense mutation near the active site that results in a valine to phenylalanine transition (V279F, \[[@B9-pharmaceuticals-02-00094]\]). A much less frequent mutation, Q281R, also results in severe deficiency of PAF-AH \[[@B6-pharmaceuticals-02-00094],[@B10-pharmaceuticals-02-00094]\]. Studies by Ishihara and co-workers revealed the occurrence of two additional loss-of-function variants, the incidence of which seems quite rare \[[@B7-pharmaceuticals-02-00094]\]. While PAF-AH deficiency alone has not been reported to have major physiological effects, several laboratories have demonstrated that a phenotype becomes evident when partial or complete deficiency is combined with other genetic defects or environmental factors, as is the case for many other gene products. Genetic studies in healthy and diseased populations indicate that PAF-AH deficiency affects the incidence and severity of a number of inflammatory diseases.

3.1. V279F (rs 16874954)
------------------------

Most subjects who express virtually no plasma PAF-AH activity harbor two F279 alleles; heterozygous subjects express half the normal plasma activity \[[@B9-pharmaceuticals-02-00094]\]. Molecular studies revealed that the recombinant mutant protein is inactive \[[@B9-pharmaceuticals-02-00094]\]. The fact that a bulky residue (phenylalanine) replaces a smaller amino acid (valine) near the active site of the enzyme likely accounts for the loss of function associated with this mutation \[[@B9-pharmaceuticals-02-00094]\]. While the initial discovery of V279F was made in a Japanese cohort, the mutation was subsequently reported in Korean \[[@B4-pharmaceuticals-02-00094]\], Taiwanese \[[@B3-pharmaceuticals-02-00094]\], and Chinese \[[@B5-pharmaceuticals-02-00094]\] populations, and in subjects from Turkey, Azerbaijan, and Kyrgyzstan \[[@B11-pharmaceuticals-02-00094]\]. Allele frequency varies widely in these populations: the highest prevalence was reported in Japan and in Taiwan, followed by Korea and China ([Table 1](#pharmaceuticals-02-00094-t001){ref-type="table"}). Our studies, and those of others \[[@B12-pharmaceuticals-02-00094],[@B13-pharmaceuticals-02-00094],[@B14-pharmaceuticals-02-00094]\], revealed that complete PAF-AH deficiency does not occur in Caucasian subjects, and this has been confirmed in public databases. This variant likely originated in Japanese and Korean ancestors. The clinical consequences associated with complete and partial PAF-AH deficiency have been evaluated in patients suffering from a variety of inflammatory conditions in the vascular, respiratory, renal, and digestive systems ([Table 1](#pharmaceuticals-02-00094-t001){ref-type="table"}). These analyses clearly demonstrated that the incidence of the F279 allele correlates with several manifestations of vascular disease in Japanese subjects; multiple studies by Yamada and co-workers and by Unno *et al.* formed the bases to support this conclusion ([Table 1](#pharmaceuticals-02-00094-t001){ref-type="table"}).
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###### 

The V279F (rs16874954) polymorphism: allele frequency in control and diseased populations.

  Population                        Clinical Status                                  n       Allele frequency, %   p                                              Authors \[Ref.\]
  --------------------------------- ------------------------------------------------ ------- --------------------- ---------------------------------------------- ---------------------------------------------------------
  Japanese                          Controls                                         263     17.9                                                                 Stafforini *et al.* \[[@B10-pharmaceuticals-02-00094]\]
  Severe asthma                     266                                              22.6    **0.02**                                                             
                                    Control adults                                   188     21.0                                                                 
  Japanese                          Control children                                 142     20.0                                                                 Ito *et al.* \[[@B15-pharmaceuticals-02-00094]\]
                                    Asthmatic children                               118     31.0                  **0.007-0.004**                                
  Japanese                          Controls                                         217     21.7                                                                 N. Satoh *et al.* \[[@B16-pharmaceuticals-02-00094]\]
  Asthma                            279                                              18.6    N/S                                                                  
  Japanese                          Controls                                         106     12.7                                                                 Unno *et al.* \[[@B17-pharmaceuticals-02-00094]\]
  Abdominal aortic aneurysm         131                                              21.4    **0.012**                                                            
  Japanese                          Controls                                         106     12.7                                                                 Unno *et al.* \[[@B18-pharmaceuticals-02-00094]\]
  Femoropopliteal bypass            50                                               21.4    **\<0.001**                                                          
  Japanese                          Controls                                         158     19.0                                                                 Unno *et al.* \[[@B19-pharmaceuticals-02-00094]\]
  Peripheral artery occl. disease   150                                              13.0    **0.031**                                                            
  Japanese                          Controls                                         114     13.0                                                                 Unno *et al.* \[[@B20-pharmaceuticals-02-00094]\]
  Atherosclerotic occl. disease     104                                              20.0    **\<0.05**                                                           
                                    Controls                                         222     12.6                                                                 
  Japanese                          Non fam. dilated cardiomyop.                     122     21.3                  **0.003**                                      Ichihara *et al.* \[[@B21-pharmaceuticals-02-00094]\]
                                    Controls                                         1,684   17.0                                                                 
  Japanese                          Risk for atherosclerosis                         1,398   18.0                  **\<0.001**                                    Yamada *et al.* \[[@B22-pharmaceuticals-02-00094]\]
                                    Atherosclerosis                                  850     22.0                  **0.0019**                                     
  Japanese men                      Controls                                         452     12.7                                                                 
  Japanese women                    Myocardial infarction                            373     18.6                  **0.0002**                                     Yamada *et al.* \[[@B23-pharmaceuticals-02-00094]\]
                                    Controls                                         150     16.3                                                                 
                                    Myocardial infarction                            81      25.9                  N/S                                            
                                    Controls                                         284     16.0                                                                 
  Japanese                          Nonfamilial hypertrophic cardiomyopathy          142     27.0                  **0.004**                                      Yamada *et al.* \[[@B24-pharmaceuticals-02-00094]\]
  Korean                            Controls                                         670     14.0                                                                 Jang *et al.* \[[@B4-pharmaceuticals-02-00094]\]
  CVD                               532                                              10.2    **0.005**                                                            
                                    Controls                                         909     5.6                                                                  
  Chinese Han                       CHD                                              808     5.0                   N/S                                            Hou *et al.* \[[@B5-pharmaceuticals-02-00094]\]
                                    Myocardial infarction                            502     5.2                                                                  
  Turkish                           Controls                                         128     1.3                                                                  Sekuri *et al.* \[[@B25-pharmaceuticals-02-00094]\]
  Premature CAD                     115                                              0       N/S                                                                  
  Taiwanese                         Controls                                         200     17.0                                                                 Liu *et al.* \[[@B3-pharmaceuticals-02-00094]\]
  Myocardial infarction             200                                              16.0    N/S                                                                  
  Japanese                          Controls                                         134     14.2                                                                 Hiramoto *et al.* \[[@B26-pharmaceuticals-02-00094]\]
  Stroke                            120                                              23.8    **0.01**              K. Satoh \[[@B27-pharmaceuticals-02-00094]\]   
                                    Controls                                         270     15.6                                                                 
  Japanese                          Cerebral hemorrhage Hypertension                 99      24.2                  **\<0.01**                                     Yoshida *et al.* \[[@B28-pharmaceuticals-02-00094]\]
                                                                                     138     19.9                  N/S                                            
  Chinese Han                       Controls                                         215     11.2                  **Statistically**                              Zhang *et al.* \[[@B29-pharmaceuticals-02-00094]\]
  Cerebral Infarction               102                                              19.0    **significant**                                                      
  Japanese                          Type 2 diabetes, 40-59 y/o                       50      14.0                  **Statistically**                              Yamamoto *et al.* \[[@B30-pharmaceuticals-02-00094]\]
  Type 2 diabetes, 60-79 y/o        50                                               30.0    **significant**                                                      
  Japanese                          Controls                                         100     16.0                                                                 Tanaka *et al.* \[[@B31-pharmaceuticals-02-00094]\]
  IgA nephropathy                   89                                               17.0    N/S                                                                  
                                    Controls                                         100     16.0                                                                 
  Japanese                          Steroid responsive nephrotic syndrome            101     12.0                  N/S                                            Xu *et al.* \[[@B32-pharmaceuticals-02-00094]\]
  Japanese                          Controls                                         100     16.0                                                                 Xu *et al.* \[[@B33-pharmaceuticals-02-00094]\]
  Hemolytic uremic syndrome         50                                               15.0    N/S                                                                  
                                    Controls                                         11      0                                                                    
  Caucasian                         Uncomplicated infection with *E. coli* O157:H7   52      0                     N/A                                            Smith *et al.* \[[@B14-pharmaceuticals-02-00094]\]
                                    Hemolytic uremic syndrome                        15      0                                                                    
  Japanese                          Control                                          108     17.0                                                                 Nakamura *et al.* \[[@B34-pharmaceuticals-02-00094]\]
  Ulcerative colitis                53                                               22.5    N/S                                                                  
  Japanese                          Control                                          188     21.0                                                                 Ohtsuki *et al.* \[[@B35-pharmaceuticals-02-00094]\]
  Schizophrenia                     191                                              19.0    N/S                                                                  
                                    Controls                                         213     14.8                                                                 
  Japanese                          Conventional MS                                  151     12.6                  N/S                                            Osoegawa *et al.* \[[@B36-pharmaceuticals-02-00094]\]
                                    Opticospinal MS                                  65      16.9                  N/S                                            
  Japanese                          Control                                          106     15.6                                                                 Minami *et al.* \[[@B37-pharmaceuticals-02-00094]\]
  Kawasaki disease                  76                                               13.2    N/S                                                                  
  Caucasian                         Randomly selected                                1,202   0                     N/A                                            Schnabel *et al.* \[[@B13-pharmaceuticals-02-00094]\]

This Table summarizes results from studies in various human populations genotyped for the V279F polymorphism. The incidence of rs16874954 is reported in terms of the percentage with which the allele was represented in healthy and diseased subjects. The "n" column refers to the number of participants in each study category and includes subjects harboring 0-1-2 polymorphic alleles. The "p" column depicts whether statistically significant differences were found in polymorphism incidence in control and diseased populations, where available/appropriate. CAD: coronary artery disease; CHD: coronary heart disease; CVD: cardiovascular disease; MS: multiple sclerosis; N/A: not applicable; N/S: Not statistically significant.

A study by Yamamoto and co-workers demonstrated that the intima media thickness in Japanese type 2 diabetics who harbored the F279 allele was significantly greater than that observed in age-matched patients who expressed wild-type PAF-AH \[[@B30-pharmaceuticals-02-00094]\]. This study suggested that F279 was associated with the development of carotid atherosclerosis in elderly diabetics. Wang and co-workers reported a significant increase in the oxLDL/LDL ratio in homozygous deficient subjects \[[@B38-pharmaceuticals-02-00094]\], suggesting that complete PAF-AH deficiency increases the susceptibility of LDL to oxidation, as previously shown in purified *in vitro* systems \[[@B39-pharmaceuticals-02-00094]\].

Some of these observations, however, were not confirmed in other laboratories. Reports by Liu *et al*. and by Hou and co-workers in Taiwanese and Chinese patients reported no association of F279 with myocardial infarction or CHD \[[@B3-pharmaceuticals-02-00094],[@B5-pharmaceuticals-02-00094]\]. The relatively low frequency of the mutant allele in the Chinese population may explain results by Hou *et al.*, as correctly pointed out by the authors \[[@B5-pharmaceuticals-02-00094]\]. In addition, the fact that neither study evaluated the results based on gender may have prevented the authors from identifying potential correlations. This is an important issue when one considers that PAF-AH deficiency has been shown to be more common in Japanese male, but not female, patients diagnosed with coronary artery disease, compared to healthy controls \[[@B23-pharmaceuticals-02-00094]\]. A study in Korean subjects reported that the frequency of F279 in this population is similar to that observed in Japan, and that this allele is less frequent in Korean men diagnosed with cardiovascular disease ([Table 1](#pharmaceuticals-02-00094-t001){ref-type="table"}, \[[@B4-pharmaceuticals-02-00094]\]). The reasons for this discrepancy are unknown, but it is possible that the criteria used for patient selection differed from those utilized in other studies.

Studies in Kei Satoh's laboratory demonstrated that the incidence of F279 is associated with stroke and cerebral hemorrhage in Japanese subjects \[[@B26-pharmaceuticals-02-00094],[@B27-pharmaceuticals-02-00094],[@B28-pharmaceuticals-02-00094]\]. Interestingly, Zhang and co-workers also reported that F279 may be an independent risk for atherosclerotic cerebral infarction in Chinese subjects \[[@B29-pharmaceuticals-02-00094]\], suggesting that the clinical impact of F279 is not limited to Japanese populations. Studies in the respiratory system revealed similar trends. We found that the incidence and severity of asthma was higher in Japanese PAF-AH deficient subjects compared to healthy controls \[[@B10-pharmaceuticals-02-00094]\]. This finding was confirmed by another group \[[@B15-pharmaceuticals-02-00094]\] but not by N. Satoh *et al*. \[[@B16-pharmaceuticals-02-00094]\]. A limitation of the study by N. Satoh *et al.* is that the prevalence of the F279 allele in control subjects was higher than that detected in most other reports in Japanese populations ([Table 1](#pharmaceuticals-02-00094-t001){ref-type="table"}). It is possible that the higher-than-normal frequency of F279 in the controls accounted for the observations reported in this study.

Additional work in patients afflicted by a variety of diseases revealed potential contributions of F279 to the severity, but not the incidence, of a number of syndromes. In these analyses, F279 was shown to contribute to disease progression rather than onset. First, while F279 was reportedly unrelated to either susceptibility or severity of conventional multiple sclerosis, it increased the severity of female opticospinal multiple sclerosis \[[@B36-pharmaceuticals-02-00094]\]. Second, Nakamura and co-workers found no significant differences in genotypic frequency of ulcerative colitis patients compared to controls \[[@B34-pharmaceuticals-02-00094]\]. However, unresponsiveness to steroid therapy was significantly higher in patients who harbored one F279 allele compared to those who did not (66.7 vs. 27.6 percent, p = 0.019). The authors concluded that F279 could be a useful marker to predict responsiveness to steroid therapy \[[@B34-pharmaceuticals-02-00094]\]. Third, no significant differences have been detected in genotype frequency between Kawasaki Disease patients and controls \[[@B37-pharmaceuticals-02-00094]\]. However, patients who harbored one or two F279 alleles required additional intravenous immunoglobulin administration (52% vs 14%, p = 0.001). Three studies reported that F279 correlates with the severity of renal diseases ([Table 1](#pharmaceuticals-02-00094-t001){ref-type="table"}). Tanaka and co-workers showed that IgA nephritic children who carried the F279 allele excreted more protein in the urine compared to patients who harbored only the wild-type allele \[[@B31-pharmaceuticals-02-00094]\]. In addition, the percentage of glomeruli with mesangial cell proliferation was significantly greater in F279 carriers, suggesting that the mutation may increase the severity of childhood IgA nephropathy \[[@B31-pharmaceuticals-02-00094]\]. Second, patients diagnosed with steroid-responsive nephritic syndrome and who harbored one F279 allele had more relapses during the first year after disease onset compared to patients who carried only the wild-type allele. This observation suggests that genotyping at this locus could facilitate identification of children likely to have a disease relapse \[[@B32-pharmaceuticals-02-00094]\]. Finally, the mean duration of oligoanuria was significantly longer in heterozygous compared to homozygous wild- type patients diagnosed with *E. coli* O157-associated hemolytic uremic syndrome (p = 0.012, \[[@B33-pharmaceuticals-02-00094]\]). Most (75%) heterozygous subjects required dialysis, while most (63%) patients who harbored only the wild-type allele did not. Interestingly, aberrant PAF production has been reported in hemolytic uremic syndrome patients. A study in Caucasians who did not harbor F279, showed a rise in PAF levels following infection with *E. coli* O157, and decreased levels of the mediator during development of the disease \[[@B14-pharmaceuticals-02-00094]\]. It is possible that the initial increase in PAF levels is followed by resolution without full disease development in subjects who can rapidly and effectively inactivate PAF. Unfortunately, this study did not assess the levels of PAF-AH activity, so it is not possible to draw firm conclusions at this point. It is tempting to speculate, however, that subjects deficient in PAF-AH activity may have more severe forms of hemolytic uremic syndrome owing to impaired abilities to inactivate PAF. In summary, results from independent studies indicate that the presence of F279 increases the severity of several renal disorders and that identification of subjects who harbor this mutation could have significant clinical value.

3.2. Q281R, I317N and Ins 191
-----------------------------

A relatively uncommon mutation (Q281R) located two amino acids downstream of the most prevalent inactivating PAF-AH mutation was shown to result in severe, but not complete, loss of enzymatic activity (\[[@B6-pharmaceuticals-02-00094],[@B10-pharmaceuticals-02-00094]\], [Figure 1](#pharmaceuticals-02-00094-f001){ref-type="fig"}). The precise incidence of this variant is likely quite low, even in Japanese populations. Previous studies suggested an allele frequency of approximately 1.0 % for this variant \[[@B7-pharmaceuticals-02-00094],[@B40-pharmaceuticals-02-00094]\]. The Q281R mutation is near the active site of PAF-AH and is therefore likely to affect proper folding in the region, thus impairing enzymatic activity. A woman who harbored two R281 alleles suffered from coronary artery disease and hypertension \[[@B6-pharmaceuticals-02-00094]\]. In addition, a patient harboring F279 and R281 alleles had severe asthma \[[@B10-pharmaceuticals-02-00094]\]. Finally, Kujiraoka *et al.* identified a diabetic subject who was heterozygous for the Q281R mutation \[[@B40-pharmaceuticals-02-00094]\]. These isolated observations are consistent with findings in subjects harboring the F279 allele and they suggest that impaired PAF-AH function correlates with the incidence of several human diseases.

Ishihara and co-workers described two rare mutations in the coding region of PAF-AH. An insertion of adenine at nucleotide 191 in exon 3 (Ins191) creates a premature termination at codon 63 and impairs PAF-AH function (\[[@B7-pharmaceuticals-02-00094]\], [Figure 1](#pharmaceuticals-02-00094-f001){ref-type="fig"}). In addition, a novel mutation in which adenine is substituted for thymine at nucleotide 950 in exon 10, results in substitution of N for I at codon 317 (I317N, [Figure 1](#pharmaceuticals-02-00094-f001){ref-type="fig"}). This mutation could theoretically create a new N-linked glycosylation site on PAF-AH, but this has not been confirmed experimentally. Ins191 and I317N impair PAF-AH secretion by macrophages isolated from subjects carrying the mutant alleles \[[@B7-pharmaceuticals-02-00094]\].

3.3. Consequences associated with complete versus partial deficiency of PAF-AH
------------------------------------------------------------------------------

An issue that merits consideration is related to the functional consequences associated with partial versus complete deficiency of PAF-AH. In certain settings, partial deficiency of the enzymatic activity may result in a disease phenotype intermediate between that of subjects harboring two wild-type alleles and that of individuals harboring two mutant alleles. However, this may not always be the case. In fact, a 50% reduction in PAF-AH levels such as that typical of subjects harboring one F279 allele, may not significantly affect the extent of substrate hydrolysis \[[@B41-pharmaceuticals-02-00094]\]. When substrate levels are relatively low (*i.e.*, nanomolar range), the rate-limiting step of the reaction is likely determined by factors other than total enzyme activity levels. Instead, the type of lipoprotein with which the enzyme associates, substrate levels, accessibility of substrates to the active site, and/or their solubility may determine the extent of hydrolysis \[[@B41-pharmaceuticals-02-00094]\]. A corollary of this observation is that *partial* deficiency of PAF-AH due to genetic, pharmacologic, or other causes may have limited functional consequences *in vivo*. Wang and co-workers correctly pointed out that it may not be appropriate to jointly analyze heterozygous and homozygous deficient subjects in clinical studies aimed at assessing the consequences of PAF-AH deficiency \[[@B38-pharmaceuticals-02-00094]\]. To rigorously determine the impact of aberrant PAF-AH expression in human diseases, it will be essential to independently compare cohorts of subjects harboring 0, 1, and 2 functional PAF-AH alleles.

4. Other Non-Synonymous and Synonymous Amino Acid Substitutions
===============================================================

In contrast to V279F, the incidence of which seems limited to defined populations, three relatively well studied non-synonymous polymorphisms \[R92H, I198T, and A379V ([Figure 1](#pharmaceuticals-02-00094-f001){ref-type="fig"}, [Table 2](#pharmaceuticals-02-00094-t002){ref-type="table"})\] occur in all populations studied so far. Affinities of the purified variants for PAF are summarized in [Table 2](#pharmaceuticals-02-00094-t002){ref-type="table"}.
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###### 

Affinity of wild-type, human PAF-AH and several variants for PAF.

  Construct     Amino acid at position 92   Amino acid at position 198   Amino acid at position 379   Km μM \[Kruse et al., (42)\]   Km, μM (our work)
  ------------- --------------------------- ---------------------------- ---------------------------- ------------------------------ -------------------
  Wild type     R                           I                            A                            7.0                            14.5
  R92H          H                           I                            A                            9.0                            12.0
  I198T         R                           T                            A                            42.0                           24.0
  A379V         R                           I                            V                            14.0                           14.0
  R92H-I198T    H                           T                            A                            11.0                           28.9
  R92H-A379V    H                           I                            V                            8.0                            12.0
  I198T-A379V   R                           T                            V                            50.0                           30.0

4.1. R92H (rs1805017)
---------------------

The presence of arginine at codon 92 as the major allele in plasma PAF-AH is observed only in humans and in mice ([Figure 2](#pharmaceuticals-02-00094-f002){ref-type="fig"}). This indicates that absolute conservation of this residue is not essential for proper function. The role played by the amino acid present at this position has been analyzed in a variety of subjects from different populations. The largest study conducted thus far (3234 subjects) detected modest but statistically significant decreases in plasma activity levels in German subjects harboring 1 or 2 H92 alleles \[[@B43-pharmaceuticals-02-00094]\]. Similar results were recently reported by Li *et al.* who analyzed a cohort of ARDS patients \[[@B44-pharmaceuticals-02-00094]\]. In contrast, studies in Chinese and European subjects revealed no effects of H92 on total plasma PAF-AH activity \[[@B5-pharmaceuticals-02-00094],[@B45-pharmaceuticals-02-00094]\]. These observations are consistent with kinetic studies by Kruse *et al*. \[[@B42-pharmaceuticals-02-00094]\] who expressed, purified, and tested the recombinant mutant protein. These investigators found that purified preparations of R92H and wild-type PAF-AH displayed similar affinities for PAF and hydrolyzed the substrate at comparable rates. While susceptibility of the mutant to substrate inhibition was much higher than that of the wild-type protein, it is clear that this was not a reflection of increased substrate affinity. Our own studies revealed that the presence of histidine at position 92 does not affect binding of PAF-AH to LDL or HDL *in vitro* ([Figure 2](#pharmaceuticals-02-00094-f002){ref-type="fig"}, \[[@B46-pharmaceuticals-02-00094]\]), and does not alter substrate affinity ([Table 2](#pharmaceuticals-02-00094-t002){ref-type="table"}).

![The R92H variant binds to human HDL and LDL *in vitro.*](pharmaceuticals-02-00094-g002){#pharmaceuticals-02-00094-f002}

These combined observations indicate that the presence of histidine at position 92 of PAF-AH has modest or no impact on optimized plasma activity levels, does not significantly affect classic biochemical properties of the protein, and does not seem to alter location. However, it would be of importance to complement these studies with lipoprotein distribution profiles in fresh plasma samples from subjects that harbor 0-1-2 H92 alleles as these analyses would definitively establish whether H92 contributes to the ability of PAF-AH to bind to lipoprotein particles *in vivo.*

Genetic studies revealed that the allele frequency of H92 varies among populations. A method of base-quenched probe for polymerase chain reaction genotyping that requires only a pair of primers and one fluorescent probe was recently described for the detection of this polymorphism \[[@B47-pharmaceuticals-02-00094]\]. In public databases, the lowest frequency (13.5%) has been reported in a Japanese cohort and the highest prevalence (35.0%) was observed in a primarily Caucasian cohort (<http://www.ncbi.nlm.nih.gov/>). Clinical studies centered on the contribution of H92 to disease incidence revealed similar frequencies of this polymorphism in healthy subjects compared to atopic and asthmatic patients ([Table 3](#pharmaceuticals-02-00094-t003){ref-type="table"}, \[[@B42-pharmaceuticals-02-00094]\]) and in patients with schizophrenia ([Table 3](#pharmaceuticals-02-00094-t003){ref-type="table"}, \[[@B12-pharmaceuticals-02-00094]\]). In addition, there seem to be no changes in the frequency of this polymorphism in patients with coronary artery diseases or myocardial infarction, compared to healthy subjects.
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###### 

The R92H (rs1805017) polymorphism: allele frequency in control and diseased populations.

  Population                                       Clinical Status     n       Allele frequency    p     Authors \[Ref.\]
  ------------------------------------------------ ------------------- ------- ------------------- ----- -------------------------------------------------------
  British                                          Controls            150     23.2                      Kruse *et al.* \[[@B42-pharmaceuticals-02-00094]\]
  Atopic asthma                                    150                 23.4    N/S                       
  German                                           Nonatopic           33      24.1                N/S   
  Atopic                                           72                  25.4    (IgE levels)              
  British                                          Controls            146     24.7                      Bell *et al.* \[[@B12-pharmaceuticals-02-00094]\]
  Schizophrenia                                    298                 25.2    N/S                       
  Caucasian                                        Controls            693     25.8                      Hoffmann *et al.* \[[@B43-pharmaceuticals-02-00094]\]
  CAD                                              2,541               26.0    N/S                       
  German                                           Controls            484     22.4                      Ninio *et al.* \[[@B45-pharmaceuticals-02-00094]\]
  CAD                                              1,303               27.1    **0.015**                 
  Caucasian + African American + American Indian   Controls            267     34.0                      Sutton *et al.* \[[@B8-pharmaceuticals-02-00094]\]
  CAD (\< 56y/o)                                   599                 28.0    **0.01-0.04**             
  CAD (\> 56 y/o)                                  207                 21.0    **0.0001-0.0002**         
  Myocardial infarction                            425                 28.0    **0.0008-0.002**          
  Chinese                                          Controls            896     17.2                      Hou *et al.* \[[@B5-pharmaceuticals-02-00094]\]
  CHD                                              806                 18.2    N/S                       
  Myocardial infarction                            499                 20.1    N/S                       
  Caucasian                                        ARDS                41      20.7                N/A   Li *et al.* \[[@B44-pharmaceuticals-02-00094]\]
  African American                                 ARDS                17      29.4                N/A   
  Caucasian                                        Controls            355     27.5                      Limou *et al.* \[[@B48-pharmaceuticals-02-00094]\]
  AIDS (slow progressors)                          168                 26.8    N/S                       
  AIDS (rapid progressors)                         54                  29.6    N/S                       
  Japanese                                         Randomly selected   1,878   21.1                N/A   Kokubo *et al.* \[[@B49-pharmaceuticals-02-00094]\]
  Caucasian                                        Randomly selected   1,183   26.8                N/A   Schnabel *et al.* \[[@B50-pharmaceuticals-02-00094]\]

This Table summarizes results from studies in various human populations genotyped for the R92H polymorphism. The incidence of rs1805017 is reported in terms of the percentage with which the allele was represented in healthy and diseased subjects. The "n" column refers to the number of participants in each study category and includes subjects harboring 0-1-2 polymorphic alleles. The "p" column depicts whether statistically significant differences were found in polymorphism incidence in control and diseased populations, where available/appropriate. AIDS: acquired immune deficiency syndrome; ARDS: acute respiratory distress syndrome; CAD: coronary artery disease; CHD: coronary heart disease; N/A: not applicable; N/S: not statistically significant.

Two exceptions include a study by Ninio *et al.* describing increased risk of coronary artery disease associated with H92 \[[@B45-pharmaceuticals-02-00094]\] and a report by Sutton *et al*. \[[@B8-pharmaceuticals-02-00094]\] that found the opposite trend, that is, a protective effect of the minor allele ([Table 3](#pharmaceuticals-02-00094-t003){ref-type="table"}). The suitability of control cohorts utilized in these two studies has been questioned owing to the fact that the frequency of the H92 allele (22.4 and 34%, respectively) differed from that observed in other studies in similar populations ([Table 3](#pharmaceuticals-02-00094-t003){ref-type="table"}) and in an unaffected cohort (n=718) of GENECARD \[[@B43-pharmaceuticals-02-00094]\]. In addition, the report by Sutton *et al.* indicated that no differential gene expression was observed in diseased arteries and showed no influence of the polymorphism on disease burden in the aorta \[[@B8-pharmaceuticals-02-00094]\]. Given that a larger recent study \[[@B43-pharmaceuticals-02-00094]\] failed to confirm the contradictory associations reported in these analyses \[[@B8-pharmaceuticals-02-00094],[@B45-pharmaceuticals-02-00094]\], it is tempting to conclude that H92 does not modulate, or has a modest impact, on vascular disease.

Recent work by Li and co-workers \[[@B44-pharmaceuticals-02-00094]\] showed that ARDS patients carrying the H92 allele were mechanically ventilated for a longer time period when compared to non-carriers. This patient group expressed 25.8% lower plasma PAF-AH activity compared to patients harboring the wild-type allele. This interesting study also reported increased survival in patients who expressed higher plasma PAF-AH levels seven days following diagnosis. The results indicate that inter-individual variability in plasma PAF-AH activity may have prognostic value and suggest that PAF-AH genotyping and assessment of plasma activity levels in critically ill patients may help in the selection of therapeutic approaches that can be tailored to the needs of individual patients.

4.2. I198T (rs 1805018)
-----------------------

Individuals harboring a threonine at position 198 of PAF-AH were first described by Bell and co-workers \[[@B12-pharmaceuticals-02-00094]\]. The degree of conservation of this residue across species is moderate ([Figure 3](#pharmaceuticals-02-00094-f003){ref-type="fig"}). Expression of the recombinant variant revealed that enzymatic activity was preserved \[[@B42-pharmaceuticals-02-00094]\]. However, the mutant protein displayed decreased affinity for PAF ([Table 2](#pharmaceuticals-02-00094-t002){ref-type="table"}, \[[@B42-pharmaceuticals-02-00094]\]). Our studies revealed that the presence of T198 did not affect binding to LDL or HDL *in vitro* ([Figure 3](#pharmaceuticals-02-00094-f003){ref-type="fig"}, \[[@B46-pharmaceuticals-02-00094]\]). As in the case of R92H, it would be of interest to complement these studies with lipoprotein distribution profiles in fresh plasma samples from subjects that harbor 0-1-2 T198 alleles, as these analyses would establish whether T198 contributes to the ability of PAF-AH to associate with lipoprotein particles *in vivo.*

Individuals homozygous for the I198T polymorphism are rare, so most of the work in humans has been conducted in heterozygous subjects. There is controversy on the impact of T198 on the levels of expression of plasma PAF-AH protein and activity. Three investigations revealed no statistically significant effect of T198 on enzymatic activity \[[@B43-pharmaceuticals-02-00094],[@B44-pharmaceuticals-02-00094],[@B45-pharmaceuticals-02-00094]\]. However, a recent study by Hou *et al*. showed that subjects harboring this variant expressed substantially lower levels of PAF-AH activity \[[@B5-pharmaceuticals-02-00094]\]. The haplotypes of these subjects differed from those of the control subjects in more than the I198T polymorphism \[[@B5-pharmaceuticals-02-00094]\] and it is not clear whether these additional genetic variations contributed to the observed decreases in activity. This is particularly important as PAF-AH risk alleles may have an additive effect that leads to the generation of dysfunctional protein products \[[@B8-pharmaceuticals-02-00094]\]. Sutton *et al.* reported a trend towards decreased PAF-AH expression in the aorta of subjects harboring T198 \[[@B8-pharmaceuticals-02-00094]\]. These observations leave open the possibility that at least in some populations, T198 affects activity and/or protein levels, or protein stability, in addition to its effect on substrate affinity.

Public databases (<http://www.ncbi.nlm.nih.gov/>) report that the lowest T198 allele frequency occurs in Caucasian (4.2--12.0%) and Asian (4.3--11.0%, excluding Japanese) cohorts. The frequency is much higher in Japanese subjects (19.7%), in African Americans (23.5%), and in sub-Saharan African populations (28.5%).

![The I198T variant binds to human HDL and LDL *in vitro.*](pharmaceuticals-02-00094-g003){#pharmaceuticals-02-00094-f003}

Kruse and co-workers found the T198 variant to be highly associated with total IgE concentrations in an atopic population and with atopic asthma in an asthmatic population ([Table 4](#pharmaceuticals-02-00094-t004){ref-type="table"}, \[[@B42-pharmaceuticals-02-00094]\]). Interestingly, T198 seems to be somewhat more prevalent in ARDS patients \[[@B44-pharmaceuticals-02-00094]\] compared to control populations with similar ethnic backgrounds ([Table 4](#pharmaceuticals-02-00094-t004){ref-type="table"}), suggesting that additional, well-controlled studies related to the impact of T198 on ARDS incidence and severity may be warranted.

The prevalence of the T198 polymorphism has been found to be weakly associated with the incidence of schizophrenia (\[[@B12-pharmaceuticals-02-00094]\], [Table 4](#pharmaceuticals-02-00094-t004){ref-type="table"}). Mechanistically, it is possible that the variant contributes to these syndromes as a consequence of decreased protein expression, at least in some populations \[[@B5-pharmaceuticals-02-00094]\]. Alternatively, since substrate concentration and/or accessibility to the active site tend to be rate limiting *in vivo* \[[@B41-pharmaceuticals-02-00094]\], decreased substrate affinity (*i.e,* increased Km \[[@B42-pharmaceuticals-02-00094]\]) may account for the observed effects.

A variety of studies have assessed the incidence of T198 in patients with cardiovascular disease ([Table 4](#pharmaceuticals-02-00094-t004){ref-type="table"}). These analyses have led to conflicting results possibly owing to the size and heterogeneity of the patient populations and/or the type of statistical analyses utilized. Sutton *et al.* used logistic regression modeling and found no significant association of T198 with CAD outcome \[[@B8-pharmaceuticals-02-00094]\]. Similarly, Ninio *et al.* reported that the incidence of cardiovascular events was not significantly associated with survival outcome by univariate analyses \[[@B45-pharmaceuticals-02-00094]\]. In contrast, Hoffmann and co-workers reported lower incidence of T198 in a CAD cohort. The larger size of the populations studied by Hoffmann *et al.* may explain why this correlation did not become evident in other studies. Kokubo and co-workers reported that the presence of T198 was associated with hypertension in women when the data were adjusted for several factors and analyzed by multivariate logistic regression analyses \[[@B49-pharmaceuticals-02-00094]\]. In summary, while there is no absolute agreement on the precise role of the somewhat rare T198 polymorphism on activity and/or disease incidence, it seems that additional large-scale studies should further evaluate whether, and how, T198 contributes to inflammatory and vascular disorders. These analyses should include activity measurements as at least one study \[[@B5-pharmaceuticals-02-00094]\] showed a remarkably high inhibitory effect of this polymorphism on PAF-AH levels. It seems that analyses in Japanese cohorts would be ideal for this purpose, owing to the reportedly high prevalence of the polymorphism in this population.

pharmaceuticals-02-00094-t004_Table 4

###### 

The I198T (rs1805018) polymorphism: Allele frequency in control and diseased populations.

  Population                                       Clinical Status     n       Allele frequency,%        p     Authors \[Ref.\]
  ------------------------------------------------ ------------------- ------- ------------------------- ----- -------------------------------------------------------
  British                                          Controls            150     7.6                             Kruse *et al.* \[[@B42-pharmaceuticals-02-00094]\]
  Atopic asthma                                    150                 11.7    **0.008**                       
  German                                           Nonatopic           33      0.8                             
  Atopic                                           72                  3.7     **0.0087** (IgE levels)         
  British                                          Controls            99      2.5                             Bell *et al.* \[[@B12-pharmaceuticals-02-00094]\]
  Schizophrenia                                    204                 6.4     **0.04**                        
  Caucasian                                        Controls            693     6.1                             Hoffmann *et al.* \[[@B43-pharmaceuticals-02-00094]\]
  CAD                                              2,541               4.4     **0.009**                       
  German                                           Controls            484     5.7                             Ninio *et al.* \[[@B45-pharmaceuticals-02-00094]\]
  CAD                                              1,311               5.4     N/S                             
  Caucasian + African American + American Indian   Controls            267     6.0                             Sutton *et al.* \[[@B8-pharmaceuticals-02-00094]\]
  CAD (\< 56y/o)                                   599                 9.0     N/S                             
  CAD (\> 56 y/o)                                  207                 7.0     N/S                             
  Myocardial infarction                            425                 8.0     N/S                             
  Chinese                                          Controls            909     8.7                             Hou *et al.* \[[@B5-pharmaceuticals-02-00094]\]
  CHD                                              808                 9.8     N/S                             
  Myocardial infarction                            502                 9.9     N/S                             
  Caucasian                                        ARDS                41      9.8                       N/A   Li *et al.* \[[@B44-pharmaceuticals-02-00094]\]
  African American                                 ARDS                17      11.8                      N/A   
  Caucasian                                        Randomly selected   1,202   5.2                       N/A   Schnabel *et al.* \[[@B13-pharmaceuticals-02-00094]\]
  Japanese                                         Randomly selected   1,878   20.7                      N/A   Kokubo *et al.* \[[@B49-pharmaceuticals-02-00094]\]
  Japanese                                         Controls            96      28.1                      N/A   Jinnai *et al.* \[[@B51-pharmaceuticals-02-00094]\]
  Caucasian                                        Randomly selected   1,202   5.2                       N/A   Schnabel *et al.* \[[@B13-pharmaceuticals-02-00094]\]

This Table summarizes results from studies in various human populations genotyped for the I198T polymorphism. The incidence of rs1805018 is reported in terms of the percentage with which the allele was represented in healthy and diseased subjects. The "n" column refers to the number of participants in each study category and includes subjects harboring 0-1-2 polymorphic alleles. The "p" column depicts whether statistically significant differences were found in polymorphism incidence in control and diseased populations, where available/appropriate. ARDS: acute respiratory distress syndrome; CAD: coronary artery disease; CHD: coronary heart disease; N/A: not applicable; N/S: not statistically significant.

4.3. A379V (rs 1051931)
-----------------------

Individuals harboring a valine at position 379 of PAF-AH were described a few years ago \[[@B12-pharmaceuticals-02-00094]\]. While humans express predominantly an alanine residue at this position, most species harbor a valine residue ([Figure 4](#pharmaceuticals-02-00094-f004){ref-type="fig"}). This feature forecasts limited impact of V379 on enzyme function in humans. Purified recombinant A379V displays increased maximal velocity and a two-fold decrease in substrate affinity compared to the wild-type protein (\[[@B42-pharmaceuticals-02-00094]\], [Table 2](#pharmaceuticals-02-00094-t002){ref-type="table"}). We found that the A379V variant associated with LDL and HDL in fashions comparable to those of the human protein ([Figure 4](#pharmaceuticals-02-00094-f004){ref-type="fig"}, \[[@B46-pharmaceuticals-02-00094]\]). However, a systematic study to characterize the lipoprotein distribution of PAF-AH in subjects homozygous for the V379 polymorphism has not, to my knowledge, been performed.

![The A379V variant binds to human HDL and LDL *in vitro.*](pharmaceuticals-02-00094-g004){#pharmaceuticals-02-00094-f004}

As in the case of other polymorphisms, there is controversy on the impact of V379 on plasma PAF-AH protein and activity levels. Hoffmann and co-workers reported increases in PAF-AH plasma levels with a clear gene-dose effect \[[@B43-pharmaceuticals-02-00094]\]. Similarly, Ninio and collaborators found that the presence of V379 was significantly associated with increased PAF-AH activity in a co-dominant fashion (p = 0.02, \[[@B45-pharmaceuticals-02-00094]\]). Schnabel and co-workers reported higher PAF-AH activity in subjects carrying two V379 alleles and extended the observation to a large community-based cohort \[[@B50-pharmaceuticals-02-00094]\]. While the observed differences were statistically significant in these two instances, the increases in activity were modest (\<10 %). Three unrelated studies found no statistically significant effect of V379 on enzymatic activity in ARDS patients ([Table 5](#pharmaceuticals-02-00094-t005){ref-type="table"}), in a Chinese cohort, and in a Caucasian control group \[[@B5-pharmaceuticals-02-00094],[@B44-pharmaceuticals-02-00094],[@B52-pharmaceuticals-02-00094]\]. An interesting study in a Taiwanese population showed dramatic decreases in activity in subjects homozygous for the V379 allele \[[@B3-pharmaceuticals-02-00094]\]. The fact that this is the only study reporting such large effects suggests that an additional factor(s) peculiar to this group of subjects likely contributed to the results. In summary, the presence of V379 may confer a very modest increase in plasma PAF-AH activity levels in some populations. These effects are likely mediated by the enzyme itself, because studies that evaluated properties of the purified recombinant A379V variant in a lipoprotein-free assay system recapitulated the increased enzymatic activity that was observed in some clinical studies \[[@B42-pharmaceuticals-02-00094]\].

pharmaceuticals-02-00094-t005_Table 5

###### 

The A379V (rs1051931) polymorphism: allele frequency in control and diseased populations.

  Population                                       Clinical Status     n       Allele frequency   p            Authors \[Ref.\]
  ------------------------------------------------ ------------------- ------- ------------------ ------------ -----------------------------------------------------------
  British                                          Controls            150     15.2               **0.038**    Kruse *et al.* \[[@B42-pharmaceuticals-02-00094]\]
  Atopic asthma                                    150                 21.6                                    
  German                                           Nonatopic           33      10.3               **0.0017**   
  Atopic                                           72                  21.9                                    
  German                                           Controls            484     24.3               **0.0007**   Ninio *et al.* \[[@B45-pharmaceuticals-02-00094]\]
  CAD                                              1298                19.5                                    
  Caucasian + African American + American Indian   Controls            267     15.0                            Sutton *et al.* \[[@B8-pharmaceuticals-02-00094]\]
  CAD (\< 56y/o)                                   599                 20.0    0.05                            
  CAD (\> 56 y/o)                                  207                 26.0    **0.002**                       
  Myocardial infarction                            425                 19.0    0.01                            
  Taiwanese                                        Controls            200     21.0               **0.01**     Liu *et al.* \[[@B3-pharmaceuticals-02-00094]\]
  Myocardial infarction                            200                 33.0                                    
  Caucasian                                        Controls            693     20.9               N/S          Hoffmann *et al.* \[[@B43-pharmaceuticals-02-00094]\]
  CAD                                              2541                21.4                                    
  Chinese                                          Controls            904     15.9                            Hou *et al.* \[[@B5-pharmaceuticals-02-00094]\]
  CHD                                              808                 16.6    N/S                             
  Myocardial infarction                            503                 15.5    N/S                             
  Korean                                           Controls            670     14.6               N/S          Jang *et al.* \[[@B4-pharmaceuticals-02-00094]\]
  CVD                                              532                 15.5                                    
  European                                         Controls            556     24.0               \--          Abuzeid *et al.* \[[@B53-pharmaceuticals-02-00094]\]
  Myocardial infarction                            527                 22.0                                    
  Caucasian                                        Male controls       359     20.2                            Wootton *et al.* \[[@B52-pharmaceuticals-02-00094]\]
  Male CHD                                         104                 21.2    N/S                             
  Female controls                                  244                 20.9                                    
  Female CHD                                       50                  23.0    N/S                             
  Caucasian                                        Early ARDS          41      13.4               N/A          Li *et al.* \[[@B44-pharmaceuticals-02-00094]\]
  African American                                 Early ARDS          17      11.8               N/A          
  British                                          Controls            93      25.8                            Bell *et al.* \[[@B12-pharmaceuticals-02-00094]\]
  Schizophrenia                                    191                 18.8    0.06                            
  British                                          Controls            123     21.5               N/A          Wootton *et al.* \[[@B54-pharmaceuticals-02-00094]\]
  British Caucasian                                Controls            2695    19.6               N/A          Rudd *et. al.* \[[@B55-pharmaceuticals-02-00094]\]
  Mixed                                            Randomly selected   8105    19.4               N/A          Schnabel *et al.* \[[@B50-pharmaceuticals-02-00094]\]
  Dutch                                            Randomly selected   3575    19.0               N/A          Van den Berg *et al.* \[[@B56-pharmaceuticals-02-00094]\]
  Japanese                                         Randomly selected   1,878   10.8               N/A          Kokubo *et al.* \[[@B49-pharmaceuticals-02-00094]\]
  Japanese                                         Controls            96      4.2                N/A          Jinnai *et al.* \[[@B51-pharmaceuticals-02-00094]\]

This Table summarizes results from studies in various human populations genotyped for the A379V polymorphism. The incidence of rs1051931 is reported in terms of the percentage with which the allele was represented in healthy and diseased subjects. The "n" column refers to the number of participants in each study category and includes subjects harboring 0-1-2 polymorphic alleles. The "p" column depicts whether statistically significant differences were found in polymorphism incidence in control and diseased populations, where available/appropriate. ARDS: acute respiratory distress syndrome; CAD: coronary artery disease; CHD: coronary heart disease; CVD: cardiovascular disease; N/A: not applicable; N/S: not statistically significant.

The prevalence of the V379 allele varies among populations. The lowest frequency (9.2--9.5%) has been reported in Japanese populations and the highest prevalence (26.7--32.6%) was observed in Sub-Saharan African subjects. A number of groups have investigated whether V379 is associated with the incidence of various diseases and/or physiological responses ([Table 4](#pharmaceuticals-02-00094-t004){ref-type="table"}). Bell and co-workers found no significant differences in allele frequency between patients with schizophrenia and control subjects, although a trend (p = 0.057) towards increased incidence in the patients was noted \[[@B12-pharmaceuticals-02-00094]\]. In contrast, V379 was found to be highly associated with specific sensitization in a German atopic population and with atopic asthma in a British cohort ([Table 5](#pharmaceuticals-02-00094-t005){ref-type="table"}, \[[@B42-pharmaceuticals-02-00094]\]). Wootton and co-workers reported that after ten weeks of intensive physical exercise, individuals homozygous for the V379 allele showed decreased percentage of adipose tissue compared to AV and AA genotype groups (p = 0.01, \[[@B52-pharmaceuticals-02-00094]\]). A potentially interesting observation by Li and co-workers is that ARDS patients seem to have a lower incidence of the V379 polymorphism compared to similar Caucasian cohorts \[13.4% versus 19.6--25.8% in control Caucasian subjects, excluding reference \[[@B42-pharmaceuticals-02-00094]\], [Table 5](#pharmaceuticals-02-00094-t005){ref-type="table"}\]. Unfortunately, this analysis only evaluated ARDS patients, so a comparison with healthy control subjects can only be made across studies. Nonetheless, the fact that ARDS survivors expressed higher plasma PAF-AH activity \[[@B44-pharmaceuticals-02-00094]\], combined with the fact that the prevalence of the V379 allele was lower in at least one ARDS cohort, suggests that V379 may offer some protection from this disease.

Eight studies investigated whether V379 contributes to vascular disease \[[@B3-pharmaceuticals-02-00094],[@B4-pharmaceuticals-02-00094],[@B5-pharmaceuticals-02-00094],[@B8-pharmaceuticals-02-00094],[@B43-pharmaceuticals-02-00094],[@B45-pharmaceuticals-02-00094],[@B52-pharmaceuticals-02-00094],[@B53-pharmaceuticals-02-00094]\]. Four of these analyses reported no statistically significant differences in allele frequency of control subjects compared to patients with coronary heart disease or myocardial infarction ([Table 5](#pharmaceuticals-02-00094-t005){ref-type="table"}). Three studies found statistically significant, but opposite, relationships between these parameters \[[@B3-pharmaceuticals-02-00094],[@B8-pharmaceuticals-02-00094],[@B45-pharmaceuticals-02-00094]\]. The suitability of control cohorts utilized in two of these reports \[[@B8-pharmaceuticals-02-00094],[@B45-pharmaceuticals-02-00094]\] was questioned by others \[[@B43-pharmaceuticals-02-00094]\], as indicated above. The lack of consensus among these analyses could be due to the criteria utilized for patient selection, combined with the size and nature of the patient populations studied. The mechanism by which potential V379-mediated effects contribute to inflammatory diseases could include direct effects of the polymorphism on enzymatic activity, but this contribution is likely to be relatively modest \[[@B45-pharmaceuticals-02-00094]\]. The possibility that V379 is in linkage disequilibrium with an un-identified etiological variant cannot be ruled out.

4.4. L12L (rs 35142331), L45P (rs 45521937), K191N (rs 45454695), and L389S (rs 34159425)
-----------------------------------------------------------------------------------------

These variants have only been reported in public databases and they occur with various frequencies in human populations. One of the variants (rs 35142331) results in no amino acid change and is thus unlikely to impact protein function. The frequency of the remaining variants is either unknown or very rare in Caucasians. The functional consequences associated with these polymorphisms are currently unknown.

5. Additional Measurements May Be Necessary to Elucidate Functional Consequences of PAF-AH Polymorphisms
========================================================================================================

5.1. Rate of hydrolysis at sub-saturating substrate levels and effect of lipoprotein environment
------------------------------------------------------------------------------------------------

We previously showed that the kinetics of PAF hydrolysis are dependent on the ratio between enzyme and substrate, and that at low substrate levels the rate of hydrolysis deviates from that predicted by Michaelis-Menten kinetics \[[@B41-pharmaceuticals-02-00094]\]. We investigated the effect of sequentially introducing naturally occurring PAF-AH polymorphisms on the kinetics of PAF hydrolysis at sub-saturating substrate levels. This analysis revealed that single, double, and triple mutants hydrolyzed PAF with similar efficiencies compared to the wild-type protein ([Figure 5](#pharmaceuticals-02-00094-f005){ref-type="fig"}, left panel).

![Kinetics of PAF (10^-9^ M) hydrolysis by free (left panel) and LDL-associated (right panel) PAF-AH variants.](pharmaceuticals-02-00094-g005){#pharmaceuticals-02-00094-f005}

In these assays, we utilized equal amounts of PAF-AH activity as determined by our standard, optimized, enzyme assay. Thus, the results were qualitatively comparable in both assay types, that is, we observed no major differences in the rate of PAF hydrolysis by PAF-AH variants. However, the experimental design in these studies did not recapitulate the environment in which the enzyme functions *in vivo*. This is an important issue because lipoproteins alter the efficiency of hydrolysis of phospholipid substrates, presumably by modulating access to the active site, altering substrate presentation, or changing solubility. To investigate this, we incorporated wild-type and PAF-AH variants into LDL, and then assessed the ability of the lipoprotein-associated variants to hydrolyze sub-saturating levels of PAF. Our studies showed that sequential introduction of each polymorphism increased the half--life of PAF in LDL ([Figure 5](#pharmaceuticals-02-00094-f005){ref-type="fig"}, right panel). These results suggested that in experimental settings modeled to mimic conditions likely to occur *in vivo*, that is, when substrate is limited, enzyme levels are in excess, and the enzyme functions in its natural environment, factors other than absolute enzyme levels impact the rate of hydrolysis. These studies revealed potentially important functional consequences associated with naturally occurring polymorphisms in PAF-AH. In addition, the results illustrate the importance of complementing traditional biochemical analyses with assays that take into consideration properties peculiar to the gene product and reaction being evaluated.

5.2. Susceptibility to oxidative inactivation
---------------------------------------------

Previous work demonstrated that PAF-AH is susceptible to inactivation by oxidants, and that key methionine and tyrosine residues confer susceptibility to oxidant attack \[[@B57-pharmaceuticals-02-00094]\]. We investigated whether naturally occurring PAF-AH variants were differentially affected by oxidants, as this could provide additional mechanistic insight into the functional consequences of genetic alterations. We expressed single, double, and triple mutants harboring R92H, I198T, and A379V, and then investigated if these polymorphic forms of PAF-AH were differentially affected by SIN-1, a peroxynitrite-generating agent \[[@B57-pharmaceuticals-02-00094]\]. We found that sequential replacement of these residues increased susceptibility to oxidative inactivation ([Figure 6](#pharmaceuticals-02-00094-f006){ref-type="fig"}). These findings suggested that subjects harboring these polymorphisms may accumulate PAF-AH substrates in settings of elevated oxidant stress that are characteristic of acute inflammation and other syndromes.

![Susceptibility of PAF-AH variants to oxidative inactivation mediated by SIN-1](pharmaceuticals-02-00094-g006){#pharmaceuticals-02-00094-f006}

6. Conclusions
==============

In this article, I have presented current information that summarizes functional and clinical consequences associated with naturally occurring variations in the PAF-AH gene. Many studies have attempted to demonstrate that genetic diversity of PAF-AH affects features related to vascular and other diseases. It is clear that mutations that compromise the normal function of the enzyme (*i.e.*, V279F) increase the incidence and/or severity of several conditions, including vascular disease, in defined populations. Superficially, this relationship may appear contrary to studies showing that *elevated* PAF-AH expression correlates with vascular disease incidence and/or severity in Western populations. However, these two sets of observations can be reconciled from a physiological perspective if increased PAF-AH expression is viewed as a compensatory, not causal, mechanism to limit damage caused by pro-inflammatory phospholipids generated in settings of high oxidant stress. PAF-AH polymorphisms that have more subtle effects in standard laboratory assays have also been reported to modulate severity or incidence of a number of syndromes and diseases. It is possible that evaluating additional enzyme properties, location, and/or functions may help elucidate whether, and how, genetic variations within the coding region of PAF-AH impact its *in vivo* function. The effect of lipoprotein location on the function of PAF-AH remains to be completely elucidated, but the fact that altered distribution has been observed in a variety of human syndromes suggests potentially important effects. This is supported by biochemical studies indicating that the environment provided by LDL allows for higher efficiency of substrate hydrolysis compared to that of HDL. Studies aimed at characterizing whether PAF-AH polymorphisms have a physiological impact should evaluate haplotypes in individual subjects rather than the prevalence of each variant in the sample set studied. This approach could have potential clinical utility as it may help identify patients most likely to benefit from therapies that target this pathway. A number of the studies cited here have used this strategy and it is likely that the approach will become standard practice. SNPs located in the promoter and other regulatory regions of PAF-AH, while not the focus of this review, may have important functional consequences as well. These variants have received limited attention and it would be interesting to evaluate whether they modulate expression levels, and/or the incidence or severity of inflammatory and vascular diseases. To establish meaningful relationships between genotype and function, and to identify the clinical impact of PAF-AH SNPs, it will be necessary to conduct systematic analyses that take into consideration individual genetic complexities, environmental influences, and the unique properties of this interesting enzyme.
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